These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29728916)

  • 1. Influence of composition of cysteine-containing peptide-based chelators on biodistribution of
    Oroujeni M; Andersson KG; Steinhardt X; Altai M; Orlova A; Mitran B; Vorobyeva A; Garousi J; Tolmachev V; Löfblom J
    Amino Acids; 2018 Aug; 50(8):981-994. PubMed ID: 29728916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.
    Altai M; Wållberg H; Orlova A; Rosestedt M; Hosseinimehr SJ; Tolmachev V; Ståhl S
    Amino Acids; 2012 May; 42(5):1975-85. PubMed ID: 21573874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
    Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
    J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator.
    Andersson KG; Oroujeni M; Garousi J; Mitran B; Ståhl S; Orlova A; Löfblom J; Tolmachev V
    Int J Oncol; 2016 Dec; 49(6):2285-2293. PubMed ID: 27748899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with
    Larkina M; Plotnikov E; Bezverkhniaia E; Shabanova Y; Tretyakova M; Yuldasheva F; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Garousi J; Gräslund T; Belousov M; Tolmachev V; Deyev S
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
    Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
    J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re.
    Altai M; Honarvar H; Wållberg H; Strand J; Varasteh Z; Rosestedt M; Orlova A; Dunås F; Sandström M; Löfblom J; Tolmachev V; Ståhl S
    Eur J Med Chem; 2014 Nov; 87():519-28. PubMed ID: 25282673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
    Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
    Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus.
    Lindberg H; Hofström C; Altai M; Honorvar H; Wållberg H; Orlova A; Ståhl S; Gräslund T; Tolmachev V
    Tumour Biol; 2012 Jun; 33(3):641-51. PubMed ID: 22249974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3.
    Oroujeni M; Bezverkhniaia EA; Xu T; Liu Y; Plotnikov EV; Klint S; Ryer E; Karlberg I; Orlova A; Frejd FY; Tolmachev V
    Nucl Med Biol; 2023; 124-125():108384. PubMed ID: 37699299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
    Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
    Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two site-specifically (18)F-labeled affibodies for PET imaging of EGFR positive tumors.
    Su X; Cheng K; Jeon J; Shen B; Venturin GT; Hu X; Rao J; Chin FT; Wu H; Cheng Z
    Mol Pharm; 2014 Nov; 11(11):3947-56. PubMed ID: 24972326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression.
    Mitran B; Altai M; Hofström C; Honarvar H; Sandström M; Orlova A; Tolmachev V; Gräslund T
    Amino Acids; 2015 Feb; 47(2):303-15. PubMed ID: 25425114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules.
    Tran T; Engfeldt T; Orlova A; Widström C; Bruskin A; Tolmachev V; Karlström AE
    Bioconjug Chem; 2007; 18(2):549-58. PubMed ID: 17330952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.
    Tolmachev V; Rosik D; Wållberg H; Sjöberg A; Sandström M; Hansson M; Wennborg A; Orlova A
    Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):613-22. PubMed ID: 19838701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
    Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
    Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins
    Larkina M; Varvashenya R; Yuldasheva F; Plotnikov E; Bezverkhniaia E; Tretyakova M; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Belousov M; Orlova A; Tolmachev V; Deyev S
    Mol Pharm; 2024 Apr; 21(4):1919-1932. PubMed ID: 38557163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake.
    Ekblad T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsén L; Wennborg A; Karlström AE; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2245-55. PubMed ID: 18594815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
    Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
    Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.
    Tran TA; Ekblad T; Orlova A; Sandström M; Feldwisch J; Wennborg A; Abrahmsén L; Tolmachev V; Eriksson Karlström A
    Bioconjug Chem; 2008 Dec; 19(12):2568-76. PubMed ID: 19035668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.